kainic acid | 62137-25-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: kainic acid
• 英文别名: kanic acid；kainate；2-Carboxy-3-carboxymethyl-4-isopropenyl-pyrrolidin；DL-α-Allocaininsaeure；α-Allokainsaeure；α-Kainic acid；3-(Carboxymethyl)-4-prop-1-en-2-ylpyrrolidin-1-ium-2-carboxylate
• CAS: 62137-25-1
• 化学式: C₁₀H₁₅NO₄
• mdl: MFCD00600019
• 分子量: 213.233
• InChiKey: VLSMHEGGTFMBBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  kainic acid 在 sodium borotritide 、 nickel dichloride 作用下， 以 四氢呋喃 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 0.5h， 以62%的产率得到
  参考文献：
  名称：

  10th international symposium on the synthesis and applications of isotopes and isotopically labelled compounds - poster presentations Session 19, Sunday, June 14 to Thursday, June 18, 2009

  摘要：

  海报会议是一系列论文，涉及之前所有会议的集合。第四届威利青年科学家奖获得者克里斯蒂安·波斯托拉赫（Cristian Postolache）在本届会议上颁发了海报。版权所有 © 2010 约翰威利父子有限公司

  DOI：

  10.1002/jlcr.1776
• 作为产物：
  描述：

  1-O-benzyl 2-O-methyl 3-(2-methoxy-2-oxoethyl)-4-prop-1-en-2-ylpyrrolidine-1,2-dicarboxylate 、 sodium hydroxide 生成 kainic acid
  参考文献：
  名称：

  TAKANO, SEIICHI;IWABUCHI, YOSHIHARU;OGASAWARA, KUNIO, J. CHEM. SOC. CHEM. COMMUN.,(1988) N 17, C. 1204-1206

  摘要：

  DOI：

文献信息

• [EN] INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE L'INDANE COMME MODULATEURS DES RÉCEPTEURS AMPA
  申请人：ORGANON NV

  公开号：WO2009147167A1

  公开（公告）日：2009-12-10

  The present invention relates to a heterocyclic derivative according to formula (I); wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.

  本发明涉及按照式(I)的杂环衍生物；其中变量如规范中定义的，或其药学上可接受的盐或溶剂。本发明还涉及包括所述杂环衍生物的药物组合物，以及它们在治疗中的使用，例如在需要增强由AMPA受体介导的突触反应的精神疾病的治疗或预防中，包括精神分裂症、抑郁症和阿尔茨海默病。
• [EN] INDANE DERIVATIVES<br/>[FR] DÉRIVÉS D'INDANE
  申请人：ORGANON NV

  公开号：WO2010115952A1

  公开（公告）日：2010-10-14

  The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said indane derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer' s disease.

  本发明涉及一种根据式I定义的邻二氢茚衍生物，其中变量如规范中所定义，或其药学上可接受的盐或溶剂。本发明还涉及一种含有一种或多种所述邻二氢茚衍生物的制药组合物，以及它们在治疗中的应用，例如在需要增强由AMPA受体介导的突触反应的精神疾病治疗或预防中，包括精神分裂症、抑郁症和阿尔茨海默病。
• HETEROCYCLIC DERIVATIVES
  申请人：Gallagher Michael Gerard

  公开号：US20090131455A1

  公开（公告）日：2009-05-21

  The present invention relates to a heterocyclic derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and learning and memory disorders such as Alzheimer's disease.

  本发明涉及一种杂环衍生物，其符合公式I，其中变量的定义如规范中所述，或其药用可接受盐或溶剂。本发明还涉及包含所述杂环衍生物的药物组合物，以及它们在治疗中的应用，例如在需要增强由AMPA受体介导的突触反应的精神疾病治疗或预防中，包括精神分裂症、抑郁症和阿尔茨海默病等学习和记忆障碍。
• Heterocyclic Derivatives
  申请人：Gillen Kevin James

  公开号：US20080255086A1

  公开（公告）日：2008-10-16

  The present invention relates to a heterocyclic derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.

  本发明涉及式I的杂环衍生物，其中变量如规范中所定义，或其药学上可接受的盐或溶剂。本发明还涉及包含上述杂环衍生物的制药组合物，以及它们在治疗中的使用，例如在需要增强由AMPA受体介导的突触反应的精神疾病的治疗或预防中，包括精神分裂症、抑郁症和阿尔茨海默病。
• INDANE DERIVATIVES
  申请人：Gillen Kevin James

  公开号：US20120202781A1

  公开（公告）日：2012-08-09

  The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said indane derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.

  本发明涉及一种按照公式I定义的indane衍生物，其中变量如规范中所定义，或其药学上可接受的盐或溶剂。本发明还涉及一种包括一种或多种所述indane衍生物的制药组合物，并且涉及它们在治疗中的应用，例如在需要增强由AMPA受体介导的突触反应的精神疾病的治疗或预防中，包括精神分裂症、抑郁症和阿尔茨海默病。